

Current report no. 36/2019

Date: 2019-12-09

Abridged name of issuer: MABION S.A.

Subject: Obtaining approval on extension of the research project deadline from the National Centre for Research and Development

Legal grounds: art. 17 section 1 of the Market Abuse Regulation – inside information.

Contents of the report:

The management board of Mabion S.A. (“Company”) hereby informs, that on the date of 9 December 2019 it learned of being granted approval from the National Centre for Research and Development (“NCBiR”) to extend the deadline of the research project entitled “Development and scaling of the innovative process of therapeutic production of recombinant monoclonal antibody in order to allow industrial implementation of the first Polish biotechnological drug for oncologic and autoimmune therapy” (“Project”) by nine months, i.e. until 30 September 2020.

The agreement to subsidise the Project was concluded on 19 September 2017 (current report no. 44/2017). The Project’s value comes to PLN 54.2 million, where the value of the subsidy (from European Funds) comes to PLN 27 million. The previous deadline of the Project was set for expiration on 31 December 2019.